46th week of 2018 patent applcation highlights part 10 |
Patent application number | Title | Published |
20180325911 | NOVEL COMPOUNDS - The invention is directed to compounds of formula (I): | 2018-11-15 |
20180325912 | METHOD OF TREATMENT OF AGGRESSION - The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity. | 2018-11-15 |
20180325913 | REJECTION REACTION SUPPRESSANT - To provide a novel method for suppressing rejection after corneal transplantation. | 2018-11-15 |
20180325914 | INCREASING STORAGE OF VITAMIN A, VITAMIN D AND/OR LIPIDS - The present disclosure provides compositions that include a nanoparticle and a compound that reduces the biological activity of one or more bromodomain and extra-terminal family member (BET) proteins (e.g., a bromodomain inhibitor), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell. | 2018-11-15 |
20180325915 | CHLOROPHYLL COMPOSITION - This invention comprises a chlorophyllin composition and method of administering the same for using the same for treatment of kidney disease patients to achieve decrease in serum creatinine level. The chlorophyllin composition and its method of administration is also for concurrent increase in blood hemoglobin level. The Chlorophyllin is selected from the group consisting of sodium copper chlorophyllin, Potassium copper chlorophyllin, Potassium Iron chlorophyllin and other metal containing chlorophyllin/s. To the chlorophyllin composition are added additives, optionally, (a) a diluent, excipient or a carrier, and optionally (b) the chlorophyllin composition is administered, either concurrently, sequentially or in any other order, with other ingredients/compositions supportive for kidney function. The dosage form of composition comprises a liquid, powder, tablet and a capsule. A kit is also provided comprising the chlorophyllin composition and the additional ingredients. The other ingredients comprise amino acids taken individually or as a mixture, protein hydrolysate, proteins or protein concentrates, vitamins and minerals. | 2018-11-15 |
20180325916 | Dermal Delivery Compositions And Methods - A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin and an estrogen, the composition contains the progestin, the estrogen and an additional anti-oxidant. Methods of improving the stability of progestin-containing compositions comprising oxidative agents are also disclosed. The methods comprise including one or more anti-oxidants in the compositions. | 2018-11-15 |
20180325917 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. | 2018-11-15 |
20180325918 | IMMUNOREGULATORY AGENT - An immunoregulatory agent containing a regulatory agent that regulates Dedicator of cytokinesis 2 (DOCK2)-mediated Rac activation as an active ingredient is provided. | 2018-11-15 |
20180325919 | ANTIFUNGAL AGENTS USED IN COMBINATION - The present invention relates to the use of enfumafungin derivative triterpenoid antifungal compounds in combination with other antifungal agents such azoles, polyenes, lipopeptides, and allylamides to treat fungal diseases. More particularly, the invention relates to antifungal combinations of enfumafungin derivative triterpenoids which are inhibitors of (1,3)-β-D-glucan synthesis, in combination with other antifungal agents such as mold-active agents that have activity against molds, including but not limited to voriconazole, isavuconazole, posaconazole, itraconazole and amphotericin B, for the treatment and/or prevention of infections caused by molds. | 2018-11-15 |
20180325920 | System and Method for Diagnosis and Treatment - This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment. | 2018-11-15 |
20180325921 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT - Provided herein are methods for treating the symptoms of and inflammation associated with gastroesophageal reflux disease (GERD) and other conditions. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 2018-11-15 |
20180325922 | 25-HYDROXY VITAMIN D3 COMPLEX AND METHODS OF MANUFACTURE AND ITS APPLICATIONS - This invention provides a 25-OH Vitamin D3 complex, this complex is made of β-cycledextrin and/or its derivatives and 25-Hydroxy Vitamin D3. This invention also relates to a method of manufacturing this complex of β-cycledextrin and 25-Hydroxy Vitamin D3, as well as its applications. Due to there being many hydroxy groups at the outside of β-cycledextrin and/or its derivatives, the complex increases the solubility of entrapped 25-HO Vitamin D3, thus increasing its bioavailability greatly. In addition, the ring structure of β-cycledextrin protects the unstable unsaturated double bonds of 25-HO Vitamin D3, shield it from oxygen and other harmful chemicals and make it much more stable. | 2018-11-15 |
20180325923 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES - The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative. | 2018-11-15 |
20180325924 | METHODS AND COMPOSITIONS FOR ENRICHING DHA LEVELS IN THE BRAIN - Described herein are at least compounds and formulations that can be or contain a docosahexaenoic acid-lysophosphatidylcholine (DHA-LPC) and/or eicosapenteanoic acid-lysophosphatidylcholine (EPA-LPC). Also described herein are at least methods of making and using the compositions and formulations DHA-LPC and/or EPA-LPC. | 2018-11-15 |
20180325925 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROINFLAMMATORY DISEASE, CONTAINING PROTEIN TYROSINE PHOSPHATASE INHIBITOR - The present invention relates to a pharmaceutical composition for prevention or treatment of a neuroinflammatory disease, in which the pharmaceutical composition includes a protein tyrosine phosphatase inhibitor. The protein tyrosine phosphatase inhibitor of the present invention inhibits activated microglia by decreasing the level of nitric oxide (NO) in the microglia and reducing the expression of proinflammatory factors, such as TNFα, IL1β, and iNOS, thereby being favorably used in prevention or treatment of the neuroinflammatory disease. | 2018-11-15 |
20180325926 | Spirocyclic Pyridotriazine Derivatives Useful As HIV Integrase Inhibitors - The present invention relates to Spirocyclic Pyridotriazine Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R | 2018-11-15 |
20180325927 | Amido-Substituted Pyridotriazine Derivatives Useful As HIV Integrase Inhibitors - The present invention relates to Amido-Substituted Pyridotriazine Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein B, X, Y, R, R | 2018-11-15 |
20180325928 | Oxidized Lipids and Treatment or Prevention of Fibrosis - The present invention is directed to methods of treating or preventing fibrosis comprising an oxidized lipid or pharmaceutical composition comprising the same. | 2018-11-15 |
20180325929 | Synthetic Composition for Treating Antibiotic Associated Complications - The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea. | 2018-11-15 |
20180325930 | Use of Oligosaccharide Compounds for Activating Angiogenesis - The subject matter of the present invention is a synthetic polysulfated oligosaccharide having 1 to 4 monosaccharaide units, salts thereof, or complexes thereof, at a concentration greater than or equal to 70 mg/mL, for use thereof for activating angiogenesis, in particular for activating angiogenesis during wound healing. | 2018-11-15 |
20180325931 | USE OF PAEONIFLORIN-6'-O-BENZENESULFONATE IN TREATMENT OF SJOGREN'S SYNDROME - The invention discloses the use of paeoniflorin-6′-O-benzenesulfonate of formula I in treatment of Sjögren's syndrome. Paeoniflorin-6′-O-benzenesulfonate of the invention, which has definitely curative effect, is characterized superiorly in that, it could be taken clinically for a long time with small dosage, mild adverse reaction and good patient compliance. The molecular formula of paeoniflorin-6′-O-benzenesulfonate is C | 2018-11-15 |
20180325932 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF - Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly. | 2018-11-15 |
20180325933 | FOOD INTAKE, BODY WEIGHT AND GLUCOSE METABOLISM REGULATION BY MODULATION OF P2Y6 RECEPTOR SIGNALING - The present invention is related to compound capable of regulating the activity of P2Y purinoceptor 6 signaling pathway, especially to compounds for inhibition of P2Y purinoceptor 6 polypeptide or inactivation, degradation, downregulation or intercalation of a nucleic acid encoding P2Y purinoceptor 6 or downregulation of P2Y purinoceptor 6 signaling pathway for the treatment of diseases related to energy balance as well as carbohydrate metabolism and homeostasis, preferably glucose metabolism and homeostasis. The present is also related to compounds for activation of P2Y purinoceptor 6 polypeptide or upregulation or modification for advanced transcriptional activity of a nucleic acid encoding P2Y purinoceptor 6, upregulation of P2Y purinoceptor 6 signaling pathway for gaining weight or for the treatment of diseases related to energy balance and carbohydrate metabolism and homeostasis. The invention is further related to methods of identifying said compounds suitable for the treatment of diseases related to energy balance and carbohydrate metabolism and homeostasis. The invention is further related to methods of treatment and diagnosis of diseases related to energy balance and carbohydrate metabolism and homeostasis and associated complications. | 2018-11-15 |
20180325934 | NEW METHOD OF TREATING BACTERIAL INFECTIONS - The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa. | 2018-11-15 |
20180325935 | NEUROCHEMICAL WELLNESS PROGRAM - A novel process for improving neurochemical health includes a multi-day treatment program including intravenous delivery of nicotinamide adenine dinucleotide (NAD) to at least partially restore a patient's brain to a desired chemical balance. Intravenous delivery of NAD is synergistically combined with delivery of selected amino acids and, depending on the ailment being treated, a combination of ozone, testosterone, glutathione, Myers cocktail or other specified compounds. | 2018-11-15 |
20180325936 | APTAMERS FOR MYCOTOXIN DETOXIFICATION - Mycotoxin-deactivating aptamers, especially DNA aptamers, bind to mycotoxins in feed and feed ingredients resulting in the reduction or elimination of toxic and carcinogenic effects of mycotoxins. The invention also discloses a composition comprising a mycotoxin-deactivating aptamer, a binding agent, a biotransforming agent and an antioxidant for detoxifying mycotoxins in feeds. In addition, the invention teaches the methods of preparing said mycotoxin-deactivating aptamer-based composition and also the methods of using it as a feed additive. Furthermore, the invention relates to the use of said mycotoxin-deactivator/s alone, or in a composition comprising said aptamers and other mycotoxin-detoxifying agents, in feeds and feed ingredients for detoxifying the major mycotoxins such as aflatoxins, deoxynivalenol, zearalenone, fumonisins and ochratoxin A. | 2018-11-15 |
20180325937 | MODULATION OF CILIOGENESIS - The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis. | 2018-11-15 |
20180325938 | METHOD OF EVALUATING OR SELECTING ANDROGEN RECEPTOR ACTIVITY REGULATOR SELECTIVE TO SEBACEOUS GLANDS OR HAIR FOLLICLES - The present invention provides a method of identifying an agent which can rapidly and accurately regulate activity of androgen receptors in a sebaceous gland- and hair follicle-selective manner. A method of evaluating or selecting an androgen receptor activity regulator selective to sebaceous glands or hair follicles, the method comprising: (A) applying a test agent to cells from sebaceous glands or hair follicles under a hypoxic condition; (B) measuring HIF1α activity in the cells; (C) comparing the HIF1α activity measured in the (B) with HIF1α activity in a control group; and (D) determining a regulatory effect of the test agent on the HIF1α activity based on the result in the (C). | 2018-11-15 |
20180325939 | POLYINOSINIC-POLYCYTIDYLIC ACID (POLY (I:C)) FORMULATIONS FOR THE TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS - The present invention concerns a composition comprising micro particles of polyinosinic-polycytidylic acid (Poly (I:C)) and a carrier polymer selected from starch, alginate, blanose or DPPC (dipalmitoylphosphatidylcholine) for use in preventing and/or treating viral infections of the upper respiratory tract or the common cold and a device, preferably a nasal delivery system, comprising said composition for use by a patient in need to prevent and/or treat infections or the common cold. | 2018-11-15 |
20180325940 | COMPOSITION FOR PREVENTING OR AMELIORATING LOSS OF HAIR AND GRAYING OF HAIR, AND USE THEREOF - The present invention provides novel compositions for suppressing or improving hair loss, and compositions for suppressing or improving graying. More specifically, it provides agents that stabilize type XVII collagen expression, preferably agents that suppress the degradation of type XVII collagen by ELANE inhibitors and such, and compositions comprising a DNA repair-promoting agent or a DNA damage-suppressing agent as an active ingredient. Advantageous suppressive effects of hair loss and graying can be obtained when a composition comprising as an active ingredient a suppressive agent of type XVII collagen degradation such as an ELANE inhibitor is administered to a mammal. For the ELANE inhibitors, suppressive agents of type XVII collagen degradation and DNA repair-promoting agents, low-molecular compounds, polypeptides, proteins, antibodies, or nucleic acid medicine such as antisense oligos or siRNAs may be used. A method of screening for effective substances for suppression of hair loss and graying is also provided. | 2018-11-15 |
20180325941 | COMPOSITION FOR REDUCING ABSORPTION OF DIETARY FAT - This invention relates to compositions for reducing the absorption or bioavailability of lipids in the gastrointestinal tract, and to methods for the preparation and use of these compositions. The compositions comprise a source of dietary fibre together with a cyclodextrin. The compositions of the invention are suitable for use in the prevention and treatment of obesity or hyperlipidaemia. | 2018-11-15 |
20180325942 | MULTICOMPONENT ORAL CARE COMPOSITION - The present invention relates to a multicomponent oral health care composition, comprising a source of a fluoride ion, a source of a calcium ion, a source of a phosphate ion, and stabilised chlorine dioxide, that can be used as a toothpaste, oral spray or a mouth wash/oral rinse formulation. The different components in the composition act synergistically together to clean the teeth and mucous membranes of an oral cavity of a subject, perfuming them or protecting them in order to keep them in good condition, change their appearance or correct unpleasant odours. They achieve this by inhibiting caries, promoting teeth remineralisation, and helping to alleviate dentine hypersensitivity, gingivitis and periodontal disease. | 2018-11-15 |
20180325943 | Biocompatible Articles With Embedded Copper Ions and Copper Ion Releasing Coating - A suture including at least one filament formed of at least one polymer and at least one copper ion at least partially embedded in the at least one filament in a manner such that the at least one copper ion is released from the at least one filament over time. | 2018-11-15 |
20180325944 | Method for preventing or treating multiple sclerosis using arsenic trioxide - The present invention relates to a method for preventing or treating multiple sclerosis, particularly relapsing-remitting multiple sclerosis using arsenic trioxide. | 2018-11-15 |
20180325945 | ORGANS FOR TRANSPLANTATION - The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells. | 2018-11-15 |
20180325946 | Composition for Treatment of Damaged Part - The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount. | 2018-11-15 |
20180325947 | USE OF MAPK INHIBITORS TO REDUCE LOSS OF HEMATOPOIETIC STEM CELLS DURING EX VIVO CULTURE AND/OR GENETIC MANIPULATION - Provided herein are methods for preparing hematopoietic stem cells (HSCs), for example, human HSCs suitable for engraftment in the presence of a p38 MAPK inhibitor. Methods for assessing engraftment of HSCs (e.g., human HSCs) are also provided. | 2018-11-15 |
20180325948 | TUMOR ANTIGEN MODIFIED DENDRITIC CELLS - Treatment of cancer is disclosed through administration of proteins or specific peptides that are uptaken by dendritic cells, wherein said dendritic cells as subsequently activated and administered, in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated proteins or peptides, followed by administration of a maturation signal in vivo. Alternatively said immature dendritic cells are grown ex vivo in an autologous or semiallogenenic manner derived utilizing conventional means and pulsed with tumor peptides disclosed herein and subsequently administered. In some embodiments of the invention said dendritic cells are treated with epigenetic modifiers to enhance antigen presentation. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor associated blood vessels. | 2018-11-15 |
20180325949 | METHOD OF MODIFYING MACROPHAGE DIFFERENTIATION AND IMMUNITY - A method of treating a cancer, the method comprising: providing a genetically modified macrophage or monocyte that contains a nucleic acid sequence encoding a Hom-1 polypeptide or a fragment thereof that contains the Hom-1 homeobox domain, wherein the nucleic acid sequence is operably linked to a heterologous promoter and the modified macrophage or monocyte expresses the Hom-1 polypeptide or the fragment thereof; and administering the modified macrophage or monocyte to a subject with a cancer. | 2018-11-15 |
20180325950 | HUCBC TREATMENT OF AMYLOID-ASSOCIATED DISEASE - Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid angiopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ | 2018-11-15 |
20180325951 | NK CELLS WITH AN INCREASED ANTIBODY-DEPENDENT CELLULAR TOXICITY (ADCC) AGAINST TUMORS - Disclosed herein are modified NK cells, compositions comprising modified NK cells, and methods for treating a tumor or hyperproliferative disease in a subject. In some embodiments, the modified NK cells include NK cells including a heterologous nucleic acid molecule encoding a CD16 protein comprising a valine at amino acid position 158 (CD16-V158), a heterologous nucleic acid molecule encoding a CCR7 protein, or both. In some embodiments, methods include treating a subject with a tumor by administering a composition comprising an anti-cancer monoclonal antibody and administering a composition comprising the modified NK cells to the subject. Also disclosed are methods of making modified NK cells by obtaining a population of NK cells from a subject and transfecting the population of NK cells with a heterologous nucleic acid molecule encoding CD16-V158, a heterologous nucleic acid molecule encoding a CCR7 protein, or both. | 2018-11-15 |
20180325952 | ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY - Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides. | 2018-11-15 |
20180325953 | MODIFIED IMMUNE CELLS AND USES THEREOF - The invention described herein relates to methods and compositions for treating cancer in a patient by administering an effective amount of cytokine receptor modified immune cells. | 2018-11-15 |
20180325954 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2018-11-15 |
20180325955 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY - Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells. | 2018-11-15 |
20180325956 | METHODS USING WHEY PROTEIN TO IMPROVE OR MAINTAIN MUSCLE QUALITY - A composition comprising whey protein and optionally Vitamin D and calcium can be administered to an individual to decrease fat deposition in muscle; increase muscle density; improve or maintain muscle quality; and/or treat or prevent muscle weakness. The composition can be administered to an elderly individual or an individual having a condition associated with increased fat infiltration in muscle to treat the condition, such as obesity. Preferably at least a portion of the whey protein is whey protein micelles, and a daily dose of the whey protein is at least 18 g. | 2018-11-15 |
20180325957 | STEM CELL THERAPY BASED ON ADIPOSE-DERIVED STEM CELLS - The present invention relates to adipose-derived stem cells (ASCs) and compositions, as well as methods for preparing and using such ASCs and compositions for therapy. | 2018-11-15 |
20180325958 | OSTEOGENIC GRAFT FORMING UNIT - Disclosed herein are compositions comprising cell-derived preparations and/or bioactive substances derived therefrom, in combination with biological carriers. Methods for making the aforementioned compositions, and methods for their use in stimulating osteogenesis and chondrogenesis in subjects in need thereof, are also disclosed. | 2018-11-15 |
20180325960 | ENHANCED POSTNATAL ADHERENT CELL, AND USE FOR SAME - The present invention relates to an enhanced postnatal adherent cell (ePAC), a method for producing same, and a composition and a cell therapeutic agent having same as an active ingredient. | 2018-11-15 |
20180325961 | ACELLULAR REGENERATIVE PRODUCTS AND METHODS OF THEIR MANUFACTURE - An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease. | 2018-11-15 |
20180325962 | ACELLULAR REGENERATIVE PRODUCTS AND METHODS OF THEIR MANUFACTURE - An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease. | 2018-11-15 |
20180325963 | BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL - The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention. | 2018-11-15 |
20180325964 | MANUFACTURING DEVICE AND METHOD OF AN IMMUNOTHERAPEUTIC FORMULATION COMPRISING A RECOMBINANT LISTERIA STRAIN - Provided herein are an apparatus and process for manufacturing a formulation comprising a drug substance, said drug substance comprising a recombinant | 2018-11-15 |
20180325965 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN - The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections. | 2018-11-15 |
20180325966 | MICROBIAL COMPOSITIONS AND METHODS OF USE FOR IMPROVING MILK PRODUCTION - The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants. In particular aspects, the disclosure provides methods of increasing desirable components of milk in ruminants. Furthermore, the disclosure provides for methods of modulating the rumen microbiome. | 2018-11-15 |
20180325967 | STABLE DRY COMPOSITIONS HAVING NO OR LITTLE SUGARS - A dry stable composition is provided. The composition comprises one or more viable microorganisms, at least 50% by weight of one or more hydrolyzed proteins and less than 10% by weight of one or more sugars selected from the group consisting of monosaccharides, disaccharides and combinations thereof, each weight percentage based on the total weight of the dry composition. Preferably, the composition comprises no monosaccharide or disaccharide. The composition may further comprise one or more oligosaccharides, one or more polysaccharides, one or more carboxylic acid salts, or a combination thereof. The composition may have viability of at least 1×10 | 2018-11-15 |
20180325968 | SKIN MICROBIOME COLONIZER FORMULATIONS AND METHODS FOR USE - A system for treating and maintaining the health of the skin of a user. The system may include a topical formulation and an oral formulation. The topical formation may include various probiotic organisms selected for enhancing and treating the skin of a user. The oral formulation may include various probiotic organisms for enhancing and treating the skin of the user. The topical formulation and the oral formulation may be used cooperatively and simultaneously to produce a beneficial, synergistic effect. | 2018-11-15 |
20180325969 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF LACTOBACILLUS PENTOSUS - A method of enhancing the barrier function of the | 2018-11-15 |
20180325970 | USE OF QUILLAJA SAPONARIA EXTRACTS FOR THE PREVENTION AND CONTROL OF BACTERIAL INFECTIONS IN FISH - The present invention provides a new use of | 2018-11-15 |
20180325971 | USE OF QUILLAJA SAPONARIA EXTRACTS FOR THE PREVENTION AND CONTROL OF VIRAL INFECTIONS IN FISH - The present invention provides a new use of | 2018-11-15 |
20180325972 | CANNABIS-HEMP BEVERAGE INFUSIONS - The present invention provides a commercial process for preparing the ‘Cannabis-Hemp Beverage Infusions’ into a soothing, impactful and pleasant beverage; that also acts as an enhanced recreational experience. The infusion process utilizes both a raw and twice-heat cooked ‘fusionable beverage’ blend that can be mixed with various fillers, herbs, and flavors; and poured into a drinking vessel of any type, or processed into a sealed drinking container for later use. | 2018-11-15 |
20180325973 | SKIN CARE COMPOSITION - The present invention relates to skin care compositions comprising extract or juice from the plant | 2018-11-15 |
20180325974 | Drug Combinations and Uses in Treating a Coughing Condition - The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions. | 2018-11-15 |
20180325975 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NAFLD/NASH - The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD), and particularly non-alcoholic steatohepatitis (NASH) comprising an ume (Japanese apricot) juice concentrate or a processed product thereof. The prophylactic and/or therapeutic agent is obtained by utilizing a component contained in a plant or a processed product thereof, and hence is safe and easily taken. It has been confirmed that when the ume juice concentrate or the processed product thereof is orally administered to a streptozocin (STZ)-induced NAFLD model mouse or an STZ-induced NASH model mouse, liver fibrogenesis can be reduced. | 2018-11-15 |
20180325976 | ANGIOGENESIS INHIBITOR - An angiogenesis inhibitor effective in inhibiting angiogenesis which causes a disease is obtained by, for example, sterilely filtrating, disinfecting, and concentrating a product which is obtained as follows. That is, rice bran is extracted with hot water, the insoluble matter is filtrated, and the starch is decomposed by processing the filtrate with glucoamylase, thereby obtaining a water-soluble polysaccharide extract. Ammonium sulfate is added to a culture filtrate prepared by culturing | 2018-11-15 |
20180325977 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF - The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases/disorders and rheumatic diseases/disorders. | 2018-11-15 |
20180325978 | USE OF COMPLEXES OF WHEY PROTEIN MICELLES AND PECTIN FOR MANAGING BODY WEIGHT - The present invention relates to a composition comprising complexes of whey protein micelles and pectin for use in the treatment or prevention of obesity or being overweight. A further aspect of the invention relates to the non-therapeutic use of a composition | 2018-11-15 |
20180325979 | PEPTIDE-INDUCED NK CELL ACTIVATION - The invention relates to a peptide capable of activating NK cell-mediated immunity, the peptide comprising or consisting of the amino acid sequence XnAX2X1, Wherein Xn is an amino acid sequence of between 5 and 12 residues, and X1 is any amino acid; or leucine or phenylalanine; and X2 is alanine, threonine or serine. The invention further relates to an MHC class I molecule and the peptide, nucleic acids encoding the peptide, activated NK cells, and related compositions and methods, including use in methods of treatment. | 2018-11-15 |
20180325980 | COMPOSITION FOR IMPROVING MEMORY, LEARNING ABILITY, AND COGNITIVE ABILITY - There is provided a composition for improving memory, learning ability, and cognitive ability. It has been confirmed that a peptide having a C-terminal region ended to GAG had an effect of improving the memory. In order for the peptide to have the effect, it has been confirmed that the peptide should be a peptide of which the length consists of at least 4 amino acids. Further, it has been confirmed that a peptide of which the length of the peptide having the C-terminal region ended to GAG consists of 5 to 9 amino acids has the same effect. As a result, the peptide of the present invention can be used as the composition for improving memory, learning ability, and cognitive ability. | 2018-11-15 |
20180325981 | AGONIST PEPTIDE FOR ADIPONECTIN RECEPTOR - A peptide includes SEQ ID NO: 1 (Xaa1-Tyr-Phe-Ala-Tyr-His-Pro-Asn-Ile-Pro-Gly-Leu-Xaa2-Tyr-Phe), wherein Xaa1 is any one selected from the group consisting of tyrosine, tryptophan, phenylalanine and non-natural amino acids having characteristics identical to tyrosine, tryptophan or phenylalanine; and Xaa2 is any one selected from the group consisting of tyrosine, tryptophan, phenylalanine, and non-natural amino acids having the characteristics identical to tyrosine, tryptophan or phenylalanine. | 2018-11-15 |
20180325982 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325983 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325984 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325985 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325986 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325987 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325988 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325989 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325990 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325991 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2018-11-15 |
20180325992 | MODULATION OF AXON DEGENERATION - The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons. | 2018-11-15 |
20180325993 | OCTREOTIDE INJECTION - The present invention relates to a sterile solution comprising: octreotide in the form of a pharmaceutically acceptable salt, present at a concentration equivalent to 2.0 mg/ml to 2.5 mg/ml of octreotide base, and at least one preservative in a pharmaceutically acceptable vehicle, wherein the sterile solution is present in an injection device. | 2018-11-15 |
20180325994 | ANTI-BACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION - Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi. | 2018-11-15 |
20180325995 | PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS - By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of lupus nephritis with voclosporin can be maximized while minimizing undesirable side effects. | 2018-11-15 |
20180325996 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 2018-11-15 |
20180325997 | COMPOUNDS FOR USE IN THE TREATMENT OF TELOMERE RELATED DISEASES AND/OR TELOMERE RELATED MEDICAL CONDITIONS - The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cancer and cellular ageing. Particularly, herein is disclosed 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in the treatment and/or prevention of cellular ageing. | 2018-11-15 |
20180325998 | DELIVERABLE EXTRACELLULAR VESICLES INCORPORATING CELL MEMBRANE TRANSPORT PROTEINS - Disclosed are extracellular vesicles (EVs), such as exosomes, comprising a heterologous cell membrane transporter protein, such as the sodium iodide symporter (NIS). Also disclosed are methods of using the disclosed EVs for delivering agents to recipient cells and methods for measuring efficacy of delivery by the EVs to the recipient cells. Also disclosed are method of making the disclosed EVs and cell lines for producing the EVs. | 2018-11-15 |
20180325999 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF - The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided. | 2018-11-15 |
20180326000 | METHODS AND COMPOSITIONS FOR MODULATING PD1 - Disclosed herein are methods and compositions for modulating expression of a PD1 gene. | 2018-11-15 |
20180326001 | Neuroprotective Peptides - The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-arg sequence or an arginine-rich peptide. | 2018-11-15 |
20180326002 | PEPTIDES DERIVED FROM KITA-KYUSHU LUNG CANCER ANTIGEN (KKLC1, CT83, CXORF61) AND COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES - The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer. | 2018-11-15 |
20180326003 | EBV ANTIGEN SPECIFIC T-CELL RECEPTOR AND USE THEREOF - The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases. | 2018-11-15 |
20180326004 | COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS - The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects. | 2018-11-15 |
20180326005 | COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS - The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects. | 2018-11-15 |
20180326006 | COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS - The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects. | 2018-11-15 |
20180326007 | COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS - The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects. | 2018-11-15 |
20180326008 | COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS - The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects. | 2018-11-15 |
20180326009 | Glial Cell Line Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions - The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof. | 2018-11-15 |
20180326010 | Immunoconjugates - The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof. | 2018-11-15 |
20180326011 | Immunoconjugates - The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and a bispecific antigen binding molecule that binds to PD-1 and Tim-3. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof. | 2018-11-15 |